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ABSTRACT
Here we describe a triple transgenic mouse system,
which combines the tissue specificity of any
Cre-transgenic line with the inducibility of the rev-
erse tetracycline transactivator (rtTA)/tetracycline-
responsive element (tet-O)-driven transgenes. To
ensure reliable rtTA expression in a broad range of
cell types, we have targeted the rtTA transgene into
the ROSA26 locus. The rtTA expression, however, is
conditional to a Cre recombinase-mediated excision
of a STOP region from the ROSA26 locus. We demon-
strate the utility of this technology through the
inducible expression of the vascular endothelial
growth factor (VEGF-A) during embryonic develop-
ment and postnatally in adult mice. Our results of
adult induction recapitulate several different hepatic
andimmunecellpathologicalphenotypesassociated
with increased systemic VEGF-A protein levels. This
systemwillbeusefulforstudyinggenesinwhichtem-
poral control of expression is necessary for the dis-
covery of the full spectrum of functions. The
presented approach abrogates the need to generate
tissue-specific rtTA transgenes for tissues where
well-characterized Cre lines already exist.
INTRODUCTION
Cellular diversity in a developing organism is achieved by
spatial and temporal regulation of gene expression determined
by genetic programs and inductive signals. As a consequence,
genes have spatially and temporally acting multiple functions,
which are difﬁcult to dissect without proper genetic tools
providing similar complexity of control of expression—
disruptionoroverexpression ofagene ofinterest(1,2). Uncon-
trolled transgenic expression of a given gene in all tissues or
even in restricted cell types may be associated with embryonic
lethality that precludes further studies at later stages of devel-
opment or in adults.
Celltype-/tissues-speciﬁcmutationofagenecanbeachieved
by a two-step process; introduction of loxP sites around a func-
tionally essential genomic part followed by a cell type-speciﬁc
Cre recombinase-mediated excision of the loxP ﬂanked
sequence. The same strategy can be used for cell type-
speciﬁc overexpression of a transgene, when a strong overall
expressing promoter is separated from the coding region of a
gene of interest by loxP ﬂanked ‘STOP’ sequences (1,3–5). In
both scenarios, a Cre recombinase transgene provides spatial
control. However, once Cre expression has been switched on
and recombination has occurred, the resultant change in gene
expressionis,inmostcases,irreversible.Tetracycline-inducible
transgenic systems [tetracycline transactivator (tTA) or ‘Tet-
Off’ and reverse tetracycline transactivator (rtTA) or ‘Tet-On’]
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(6,7). Of the two systems, rtTA is better suited for rapid
induction of gene expression.
In the following report, we describe a novel system that
allows for the spatial and temporal regulation of transgene
expressioninvivobycombininganyoftheexistingCrerecom-
binase transgenic lines with the reverse tTA (rtTA)–tet-O sys-
tem. We targeted rtTA into the widely expressed ROSA26
locus, in a way where rtTA expression is conditional to a
Cre-mediatedexcisionevent(8).Furthermore,wedemonstrate
the tightness and inducibility of this approach by systemic and
celltype-speciﬁc(neuronalandpodocyte)inducibleexpression
of a dosage-sensitive gene, VEGF-A (9). The presented mouse
line can be used to achieve spatially and temporally controlled
transgene expression in a wide variety of settings simply by
crossing to any existing mice carrying cell type-speciﬁc Cre
recombinase and tet-O-regulatable responder genes.
MATERIALS AND METHODS
DNA constructs
An EcoRI fragment carrying the rtTA coding sequence and an
N-terminal nuclear localization signal was excised from the
plasmid pSPC-rtTA (10), blunted by Klenow enzyme and
inserted into the pCALL2-IRES-EGFP plasmid (a gift from
Dr Corrine Lobe) at a blunted XhoI site. The resultant vector
(pCALL2-rtTA-IRES-EGFP) was ﬁrst digested with BglII,
ﬁlled in by Klenow polymerase and then cut with NotI, and
the fragment containing rtTA-IRES-EGFP was isolated. The
pBigTvector(11)wasdigestedﬁrstwithSalI,ﬁlledinandsub-
sequently digested with NotI. The above fragment was inser-
ted into this vector resulting in pBigT-rtTA-IRES-EGFP. The
whole insert of the latter vector was released by AscI–PacI
double digest and inserted into pROSA26-PA vector (11)
digested by the same enzymes. The resultant target vector
was named pROSA26-rtTA (Figure 1A). Before introduction
into mouse embryonic stem (ES) cells, the vector was linear-
ized with XhoI.
The murine podocin promoter was ampliﬁed from genomic
murine DNA as described previously (12) and cloned
upstream of the NLS-Cre transgene (a gift from B. Sauer).
ES cell manipulation
R1 mouse ES cells (13) were maintained and manipulated as
described elsewhere (14). In brief, 20 mg of linearized target
vector was electroporated into 10
7 cells using 500 mF and
250 V settings on Gene Pulser (Bio-Rad). After 24 h, the cells
were selected for neomycin resistance in G418 (170 mg/ml) for
8 days. The resistant colonies were picked, expanded and split
in 96-well plates, and the master plates were frozen and stored
at  80 C until genetic characterization identiﬁed the correctly
targeted clones. Some of these targeted clones were thawed
from the master plates, expanded and subjected to further
procedures described below.
To activate rtTA expression from the ROSA26 locus, the
transfection of the selected targeted clones with the pCAGGS-
Cre-PGK-puro vector (a gift from C. Lobe) was performed
using Lipofectamine 2000 (Invitrogen). An aliquot of 2 mg
circular plasmid was transfected into cells growing in a 35 mm
diameter dish. During the transfection, OPTI-MEM medium
was used. Puromycin selection (1.25 mg/ml) was applied, and
resistant colonies expanded. Green ﬂuorescence was detected
as described previously (15).
The pBI-3 plasmid (a gift from H. Bujard) contains a
bi-directional tetracycline-responsive element followed by
the lacZ coding sequence. This vector was introduced into
ES-cells by lipofection according to the protocol above.
After 5 h of transfection, doxycycline (Sigma) was added
to the medium in differing concentrations. The day after lipo-
fection, the cells were passaged 1:5 and cultured for a further
1–2 days in the presence of doxycyline (100 ng/ml), and then
stained by using X-gal.
Generation of transgenic animals
Chimeric mice were generated by aggregation of targeted
ES-cells with eight-cell stage embryos as described previously
(16). Germline transmitting chimeric males were crossed
with outbred ICR females and the offspring were genotyped
by Southern blotting and PCR for the transmission of the
transgene.
The Cre-recombinase transgenic founder lines were gener-
ated as described previously (17). Regarding the Podocin-Cre
transgene four individual founder lines were crossed with the
Z/EG reporter strain (15) to determine the degree and timing
of Cre-mediated DNA excision in podocytes.
Genotyping by Southern blotting
To detect targeting of the ROSA26 locus, genomic DNA was
isolated from the ES cells grown on 96-well plates (18), diges-
ted with EcoRV and the fragments separated on 0.7% agarose
gel. Southern blotting was performed as described previously
(19). Brieﬂy, the DNA was transferred onto a nitrocellulose
membrane (Hybond N; Amersham) and hybridized with a
probe complementary to a sequence upstream of the 50 homo-
logy arm of the vector (external probe) or with a probe com-
plementary to the neo gene (internal probe) (Figure 1A and B).
The radioactive signal was detected by phosphorimaging. To
detect the mutation in mice, 10 mg genomic DNA was extrac-
ted from mouse tail biopsies and analyzed by Southern hybrid-
ization as above.
Genotyping by PCR
PCR was performed in 25 ml reaction mixture containing
standard PCR buffer, 1.0 mM MgCl2, 200 mM dNTPs, 200 nM
primers, 5 U Taq polymerase and 100 ng genomic DNA iso-
lated from mouse ear biopsies. The primers for detection of
the targetedROSA26allele containing the STOP cassette were
as follows: ROSA5, GAGTTCTCTGCTGCCTCCTG; and
RTTA3, AAGACCGCGAAGAGTTTGTC. The reaction res-
ulted in a 215 bp band. The wild-type ROSA26 allele was
detected by an amplicon of 322 bp using primers ROSA5 and
ROSA3: CGAGGCGGATACAAGCAATA. The PCR pro-
gram was as follows: initial denaturation for 1 min at 94 C
followed by 35 cycles of 1 min at 94 C, 45 s at 62 C (knock-in
allele) or 64 C (wild-type allele) and 1 min at 72 C and a ﬁnal
extension of 5 min at 72 C. PCR products were detected on
2% agarose gel.
Histology
The X-gal staining of ES cells was performed as described
previously (15). Embryonic and adult tissue samples were
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a plasmid containing a tet-O-lacZ transgene. (D) No doxycycline induction. (E) Cells after doxycycline administration (100 ng/ml for 2 days).
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the sampleswere washedextensively with1·PBS,dehydrated
through graded alcohol washes and embedded in parafﬁn wax
as described previously (20). Sections (7 mm) were deparafﬁn-
ized and stained with Harris’ Hematoxylin and Eosin (Sigma
Immunochemicals).
RESULTS AND DISCUSSION
Generation of the ROSA26-rtTA knock-in ES cell line
We inserted an artiﬁcial exon between the ﬁrst and the second
exons of the mouse ROSA26 locus by gene-targeting. Of the
140 G418 resistant colonies picked and genotyped, 12 (8%)
were correctly targeted (Figure 1A and B). In the artiﬁcial
exon, a loxP site-ﬂanked selectable marker (neo) precedes two
coding sequences separated by an internal ribosomal entry site
(IRES). The upstream sequence is coding for rtTA with a
nuclear localization signal, and the downstream sequence is
coding for enhanced green ﬂuorescent protein (EGFP). Trans-
lation of the latter is ensured by the IRES sequence. Before
Cre-excision, the three consecutive polyadenylation signals of
the selectable marker terminate mRNA synthesis and, there-
fore, the downstream coding sequences are not expressed (8).
After Cre-mediated deletion of the loxP ﬂanked sequence,
however, rtTA and EGFP are expressed by the ROSA26 pro-
moter. Presence of doxycycline results in the formation of an
active transcriptional activator and the activation of the
responder transgene (see Figure 2).
Assessment of tetracycline-inducibility in vitro
To test the inducibility of the system in vitro, we removed
the loxP ﬂanked sequence by transfecting 10 targeted ES cell
lines with a plasmid expressing Cre recombinase as well
Figure 2. OperationoftheCre/loxP-dependent,tetracyclineinducibletransgenicsystem.(A)Micethatarehomozygousforthetargetedinsertionoftheconditional
rtTA-IRES-EGFP bicistronic transgene at ROSA26 can be bred with double transgenic mice that carry a tissue-specific Cre transgene and a doxycycline-inducible
rtTA-dependent tet-O-GENE responder line. A total of 25% of the pups will be triple transgenic (SpecPromoterCre
Tg/+, ROSA26-STOP-rtTA-IRES-EGFP
Tg/+,
tet-O-GENE
Tg/+). (B) In cells that do not express Cre, neither rtTA nor EGFP protein is generated; therefore, the tet-O-GENE is silent. (C) In Cre-expressing cells,
rtTA and EGFP expression is turned on. However, in the absence of an inducer (e.g. doxycycline), rtTA cannot activate the expression of the tet-O-GENE target.
Addition of doxycycline resultsin the formationof an active transactivatorand expressionof the target gene. In the present study, VEGF-A-164was induced either
ubiquitously or nervous system or podocyte specifically in the presence of doxycycline.
e51 Nucleic Acids Research, 2005, Vol. 33, No. 5 PAGE 4 OF 10as puromycin acyltransferase (pCAGGS-Cre-PGK-Puro). We
isolated stable integrants using puromycin selection and
veriﬁed that they displayed green ﬂuorescence while the
parental cell lines were not ﬂuorescent (Figure 1C and data
not shown). There was no difference among the different
targeted cell lines. Next, we expanded the ﬂuorescent Cre-
excised subclones of two original lines (1C12 and 1H6) and
transfected them with a vector containing a lacZ transgene
driven by a rtTA-responsive promoter (tet-O-LacZ). (We
did not use any selection for transfectants in this experiment.)
We did not observe any X-gal activity in the absence of the
inducer (Figure 1D). When the medium was supplemented
with 100 ng/ml doxycycline, LacZ positive cells were detected
(Figure 1E).
Inducible overexpression of VEGF-A in vivo
Two ES-cell clones were used to generate chimeric mice by
ES cells , embryo aggregation. In both experiments, germ-
line transmission was obtained. Heterozygous animals of both
lines were healthy, fertile and had a normal lifespan. Hetero-
zygotes from one of the lines (1C12) were intercrossed, res-
ulting in litters of pups with a Mendelian distribution of the F2
genotypes. Homozygous transgenic animals were healthy and
fertile and were used to maintain this line in the homozygous
state.Thesehomozygous,Cre-conditionalROSA26-rtTAmice
were used in consecutive experiments.
In order to test the in vivo ‘silent but inducible’ nature of the
conditional ROSA26-rtTA-IRES-EGFP transgene and rtTA
protein activity, male mice that were homozygous for the
Cre-conditional ROSA26-rtTA allele were bred with female
mice that were double heterozygous for a tet-O-VEGF-A-164
responder transgene (21) and either the ubiquitous Cre-deletor
line (pCAGGS-Cre
Tg/+) (5) or a nervous system speciﬁc
(Nestin-Cre
Tg/+) (22) or a podocyte speciﬁc (Podocin-Cre
Tg/+)
Cre line. Figure 2 describes how the three transgenes work to
unite the Cre/loxP and tetracycline inducible systems.
Since the pCAGGS-Cre transgene expresses Cre in all
the cells of the early embryo, it activates an overall rtTA
and EGFP expression as shown for a E9.5 day embryo
in Figure 3B and E. On the other hand, breeding with the
Nestin-Cre or Podocin-Cre line resulted in embryos/animals
with neuronal lineage or glomerulus-speciﬁc expression
of rtTA and EGFP, respectively, as shown in Figure 3G
for a E10.5 day embryo for Nestin-Cre and in Figure 3J for
a newborn glomerulus for Podocin-Cre. In the absence of
Cre-mediated excision of the loxP-ﬂanked PGK-neo-pA
sequence blocks rtTA and EGFP expression.
We made use of the tight dosage sensitivity of the early
developing embryo to increased (9,23) or decreased levels of
VEGF-A (20,23–26) to demonstrate the correct activation of
our inducible system. In the absence of the rtTA-inducer doxy-
cycline, triple transgenic pCAGGS-Cre
Tg/+, ROSA26-rtTA-
IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ embryos (Figure 3A
and B) develop normally and show no phenotype. However, in
the presence of doxycycline that was administered to pregnant
females starting one day after mating (E1.5), all of these triple
transgenic embryos showed lethality (Figure 3D and E and see
Table 1) at E9.5. The phenotypes of these mutant embryos
were quite severe with no primitive red blood cells (RBCs)
observed in the developing yolk sac (Figure 3D) and embryos
were blocked in development. Unlike the original homo-
zygous VEGF-A mutants that showed a severe reduction of
blood island development in the yolk sac (24,25), ubiquitous
VEGF-A-164 expression in this triple transgenic inducible
system led to enlarged blood islands in the yolk sac that were
ﬁlled with nucleated erythroblast progenitors (Figure 3F).
The normal blood islands that developed in the non-induced
embryos showed clearly deﬁned endodermal and mesodermal
layers‘sandwiching’thedevelopingbloodislands(Figure3C);
however, in the doxycycline-induced embryos, aberrant
blood islands formed (Figure 3F). All the 10 triple transgenic
embryos showed the same mutant phenotype described above
upon doxycycline administration to their mothers (Table 1).
Out of the 22 remaining littermates that were either single or
double transgenic for the three transgenes, 20 appeared totally
normal. Two rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+,
Cre-negative embryos (as judged by Southern hybridization
and PCR, data not shown), however, were also EGFP express-
ers indicating that rtTA expression activation (Cre-excision)
occurred by maternally produced Cre protein. This known
phenomenon is a consequence of high-Cre production and
accumulation during oogenesis (27).
The ubiquitous systemic administration or induction of the
VEGF-A-164 protein, or injection of tumor cells expressing
high levels of VEGF-A-164 protein into adult mice, results in
severe edema (28–30), defects in immune cell function includ-
ing destruction of the thymus (31–33) and liver pathologies
that closely resemble the human syndrome known as peliosis
hepatis that has been described in association with Bartonella
henselae infection, long-term high-dose androgen therapy,
or rarely with advanced cancers (34). In order to determine
if doxycycline-induced overall VEGF-A-164 expression could
mimic some or all of these previously described phenotypes,
triple transgenic pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-
EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ mice were allowed to
reach adulthood and a regimen of doxycycline administration
was followed (Table 1). These triple transgenic mice were
born in a normal Mendelian frequency and showed no sign
of any phenotypic abnormalities (Figure 4A–C and G–I, and
data not shown). Upon administration of doxycycline in the
drinking water to 3–4 month old pCAGGS-Cre
Tg/+, ROSA26-
rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ mice, several
phenotypes became apparent already after 2 days of treatment.
The mice showed signs of edema and erythema of the face,
ears and feet (data not shown). By 5 days of doxycycline
administration, three of the eight triple transgenic mice had
died and three were so moribund and sickly in appearance that
they had to be euthanized and their organs were harvested for
further histological analysis. Two mice seemed more resistant
to the doxycycline administration and were given the drug
for an additional 4 days at which time they too became mori-
bund and were as well sacriﬁced. Of the 10 single and double
transgenic littermates, 9 were completely normal and showed
no adverse side affects to the doxycycline administration.
Similar to what was observed in the E9.5 embryos, one
rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+, Cre-negative
adult mouse died during doxycycline administration. This
mouse, however, was EGFP positive, indicating the rtTA
expression activation by zygotic (maternal) Cre protein (27).
Upon autopsy, the most obvious gross phenotypes observed
were an extended blood ﬁlled liver and a dramatic decrease in
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signs of hyper-vascularity/permeability and edema in several
other organ systems as well as blood in the intestine (data not
shown).
Histological analysis of the liver of uninduced pCAGGS-
Cre
Tg/+,ROSA26-rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+
adult mice (control) revealed normal hepatic architecture
(Figure 4A–C). Doxycycline-treated mutant pCAGGS-Cre
Tg/+,
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Figure 3. Tissue-specific expression of the rtTA-IRES-EGFP bicistronic transgene is Cre-dependentand the rtTA trans-activationof tet-O-VEGF-A-164 is tightly
regulated by doxycycline.(A–C) Images of triple transgenic pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ E9.5 embryoand yolk sac
intheabsenceofdoxycycline:(A),Wholemountbrightfieldmicroscopy;(B),GFPfluorescencemicroscopy;and(C),H&Ehistologicalsectionoftheyolksac.Inthe
absence of doxycycline, triple transgenic embryos develop normally. Arrow in (A) shows normal yolk sac vessel with primitive hemoglobin-containing RBCs and
normal bloodisland(BI)formationbetween theprimitiveendoderm(e) andmesoderm(m) layersofthe yolksac (C). (D–F) Tripletransgenicembryoandyolk sac,
themothertreatedwithdoxycycline.(D),Wholemountbrightfieldmicroscopy;(E),GFPfluorescencemicroscopy;and(F),H&Ehistologicalsectionoftheyolksac.
(D) In the presence of doxycycline the triple transgenic embryos show a lethal phenotype with no proper vessel development in the yolk sac (ys) and embryo (e),
no hemoglobin-containing RBC (D) and abnormal blood island (BI) structures that are filled with excessive nucleated erythroblasts (EB). (B and E) The overall
EGFP signal marks the overall rtTA expression in the yolk sac and embryo of the triple transgenic embryos. (G) E10.5 triple transgenic Nestin-Cre
Tg/+, ROSA26-
rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+embryosdevelopnormallyintheabsenceofdoxycyclineandshownervoussystemspecificexpressionofEGFP/rtTA.
(H and I) E12.5 triple transgenic embryos when the mother was either non-treated (H) or treated (I) with doxycycline during the pregnancy. The VEGF-A-164
induced embryo (I) shows hemorrhages in the developing nervous system (arrows). (J) Immunostaining for EGFP shows the podocyte specificity of Podocin-Cre
excision.
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Tg/+, tet-O-VEGF-A-164
Tg/+ adult
livers showedadramatic ‘peliosis-like’phenotype(Figure4D)
and signs of blood pooling in large areas of the liver (arrows in
Figure 4E). This liver peliosis phenotype is characterized by
enlarged hepatic sinusoids and a total disruption of the normal
liver architecture (Figure 4D–F) as well as detached sinusoidal
endothelial cells that are ‘sloughing-off’ into the sinusoidal
space (arrow in Figure 4F). The liver pathology described here
resembles the liver peliosis-like pathology recently described
in mice that had been engrafted with tumor cells expressing
high levels of systemic VEGF-A-164 protein (34). In addition,
LeCouter et al. (35) have observed similar (although less
severe) liver enlargement phenotypes and effects on the sinus-
oidal endothelium of the liver with systemic administration of
recombinant VEGF-A protein. It was also demonstrated that
VEGF-A at lower doses can act on the sinusoidal vasculature
(via Flt1) to inﬂuence secretion of hepatocyte growth factor
(HGF) and may have a beneﬁcial protective effect on hepa-
tocytes under times of cytotoxic stress (35). Our VEGF-A
inducible system with liver-speciﬁc Cre lines such as the
albumin-Cre line (36) will be useful in determining the
optimal dosages of VEGF-A required for its beneﬁcial action
on the liver under times of cytotoxic stress and may at higher
induction levels be a useful model system to unravel the
molecular mechanisms behind VEGF-A’s harmful effects
on the liver.
The thymus of non-induced pCAGGS-Cre
Tg/+, ROSA26-
rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ adult mice
(control) displayed a normal thymic architecture with a
well-deﬁned cortical layer rich in basophilic thymocytes
and a normal epitheloid-rich medullary zone (Figure 4G–I).
Total average cell counts for two control thymi were
1.33 · 10
8 cells/ml (1.05 · 10
8 and 1.6 · 10
8 cells/ml in the
two different controls). Representative histological analysis of
the thymi of VEGF-A-164-induced mutant adults (Table 1)
revealed a dramatic decrease in cellularity that correlated with
its decreased size (Figure 4J–L). The mutant thymi lacked
major histological distinctions between the medullary and
cortical layers and the basophilic cortical layer that is usually
rich in thymocytes was almost completely absent (Figure 4L).
Total average cell counts for three mutant thymi were 1.37 ·
10
7 cells/ml (3.9 · 10
7, 8.1 · 10
5 and 1.14 · 10
6 cells/ml per
animal). These numbers may under-represent the acellularity
of the mutant thymi as two of the higher values were from the
two animals that survived the initial ﬁve-day period of doxy-
cycline treatment. The lower cell count of 8.1 · 10
5 cells/ml
from one of the original sick animals that had to be euthanized
in the ﬁrst ﬁve-day period may be more representative of the
acellularity shown in Figure 4J–L. The thymic atrophy presen-
ted in this paper phenocopies previous reports concerning the
detrimental effects that systemic VEGF-A has on T-cell devel-
opment (33). In addition, ubiquitous expression of VEGF-A-
164 during early development seems to give rise to increased
numbers of erythroblasts and may inhibit the differentiation
of these progenitors. From this study, it is not clear whether
this phenotype is caused by alterations in the yolk sac envir-
onment or by artiﬁcial VEGF-A-164 autocrine loop created.
We are currently investigating the molecular mechanisms
behind VEGF-A’s suppressive effects on different hemato-
poietic populations through the use of this transgenic system
together with additional hematopoietic lineage-speciﬁc Cre
lines (37,38).
The developing nervous system is also sensitive to altered
VEGF-A expression, We have recently demonstrated that
downregulation of the level of this growth factor, using a
Nestin-Cre transgene and a conditional targeted allele of
VEGF-A, have severe consequences to cortical vessel density
and structure (39). The Nestin-Cre
Tg/+, ROSA26-rtTA-IRES-
EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ triple transgenic embryos
presented here developed vascular abnormalities by E12.5,
Table 1. Summary of doxycycline induction experiments during development and in adult mice
Genotype Age n Protocol/phenotype
Triple transgenics; constitutive rtTA embryos:
pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+,
tet-O-VEGF-A-164
Tg/+
E9.5 10 Doxycycline was given to pregnant females starting at day E1.5 and mice
weredissectedatdayE9.5.All10tripletransgenicembryosshowedsigns
of embryonic lethality and were ubiquitously green
Single or double transgenic embryos (control):
ROSA26-rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+
OR ROSA26-rtTA-IRES-EGFP
Tg/+ OR
pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+
E9.5 22 DoxycyclinewasgiventopregnantfemalesstartingatdayE1.5andmicewere
dissected at day E9.5 20/22 embryos analyzed were normal. The 2/22
ROSA26-rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+, Cre-negative
embryos were ubiquitously green and showed embryonic lethality
Triple transgenics constitutive rtTA adults:
pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+,
tet-O-VEGF-A-164
Tg/+
3–4 months 8 After 2 days of doxycycline administration in drinking water all mice
appeared lethargic and sick and showed signs of edema in face and feet.
Ears appeared swollen and red. After 5 days of doxycycline
administration, 3 mice were found dead in cage and 5 others had to be
sacrificed due to moribund appearance
Single or double transgenic adults (control):
ROSA26-rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+
OR ROSA26-rtTA-IRES-EGFP
Tg/+ OR
pCAGGS-Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+
3–4 months 10 All mice (1 ROSA26-rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A164
Tg/+
Cre-negativeanimalbecameillsimilartothetripletransgenicmice)were
phenotypically normalthroughout the 5 days of doxycycline administration
Triple transgenics nervous system rtTA adult:
Nestin-Cre
Tg/+, ROSA26-rtTA- IRES-EGFP
Tg/+,
tet-O-VEGF-A-164
Tg/+
3–4 months 6 All mice were grossly normal throughout the 5 days of doxycycline
administration
Single or double transgenic adults (control):
ROSA26-rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+
OR ROSA26-rtTA-IRES-EGFP
Tg/+ OR Nestin-Cre
Tg/+
3–4 months 6 All mice were normal throughout the 5 days of doxycycline administration
TripletransgenicspodocytertTAadult:Podocin-Cre
Tg/+,
ROSA26-rtTA-IRES-EGFP
Tg/+,tet-O-VEGF-A-164
Tg/+
4 months 5 All developed nephrotic-range proteinuria (>5 g/l) 7 days after doxycycline
administration started
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doxycycline was administered to their mother from 1.5 dpc
of pregnancy (Figure 3H and I). Without doxycycline admin-
istration to the mother, these embryos developed normally and
reached adulthood. Interestingly, when these mice received
doxycycline for 5 days at 4 months of age, they did not show
any obvious gross behavioral or phenotypic abnormalities.
Initial vessel and histological analysis from two of the six
Figure 4. Liver peliosis-like phenotype and thymus degeneration are associated with the doxycycline-induced overall VEGF-A-164 expression in adult pCAGGS-
Cre
Tg/+, ROSA26-rtTA-IRES-EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ mice. H&E histological analysis of livers of triple transgenic adult mice of (A–C): VEGF-A-164
non-induced( DOX)and(D–F):VEGF-A-164induced(+DOX)bydoxycyclinetreatment.Withoutdoxycyclintreatment,livershaveanormalhepaticarchitecture
with well-defined vasculature and normal hepatic venules (V) and hepatic sinusoids (HS) (C). The doxycycline-treated mutant livers show major disruptions of
normalhepaticarchitecturewitha severedilationofhepaticsinusoids(HS)(F)andevidenceof bloodengorgementandpooling[arrowsin (E)].Arrowin (F)shows
evidence of sinusoidal endothelial sloughing and detachment. (G–I): H&E histological analysis of VEGF-A-164 non-induced ( DOX) and (J–L): VEGF-A-164
induced (+DOX) thymus of triple transgenic adult mice. Without doxycycline treatment the thymus shows normal thymic architecture with a well-defined cortex
layer (cx) that is packed with basophilic lymphocytes and a normal medullary layer (m) that contains fewer lymphocytes but an extensive epithelial framework.
Doxycycline-treatedmutantthymusshowsmassivedegenerationwithallthreethymiclobesfittingintoasingleopticalfield(J)comparedwithonethymiclobefitting
into the optic field at the same magnification (G) from control mice. In addition, the mutant thymus lacks a well-defined cortical layer owing to a dramatically
decreasednumberofbasophilicthymocytesseenathighermagnifications(L)comparedwith(I).(A,D,GandJ),50·magnification;(BandE),125·magnification;
(H and K), 250· magnification; and (C, F, I and L), 500· magnification.
e51 Nucleic Acids Research, 2005, Vol. 33, No. 5 PAGE 8 OF 10treated adult mouse brains did not reveal any striking
differences in vessel architecture or structural organization
of the cortex (data not shown). This result may indicate an
increased resistance of the adult CNS vasculature to VEGF-A.
We are currently further examining the potential effects of
doxycycline-induced increases of VEGF-A-164 and its effects
on the developing and adult nervous system using this triple
transgenic system.
In contrast, the Podocin-Cre
Tg/+, ROSA26-rtTA-IRES-
EGFP
Tg/+, tet-O-VEGF-A-164
Tg/+ triple transgenic mice trea-
ted with doxycycline for 7 days starting at 4 months of age
developed proteinuria (albumin >5 g/l, data not shown). The
presence of albuminuria in concentrations >3 g/l is designated
‘nephrotic range proteinuria’. This degree of proteinuria rep-
resents loss of the permeselective function of the glomerular
ﬁltration barrier. Increased permeability in the glomerulus
leads to the loss of critical blood proteins, including albumin,
blood clotting factor inhibitors and lipids, and is associated
with edema and thrombotic events in patients. These mice
are currently under detailed phenotypic analysis to identify
the nature of changes in the kidney caused by induction
VEGF-A expression in podocytes.
Table 1 displays the results of all the experiments described
above. In summary, by combining existing tissue-speciﬁc
Cre-transgenic mouse strains to deﬁne spatial, and the
tetracycline-inducible system to deﬁne temporal aspect of
transgene expression, we have developed a versatile system
which allowsquickandefﬁcient investigationofmultiplegene
functions. This aim has also been addressed by others using
hormone-activated Cre proteins (40,41). The major advantage
of these earlier efforts lie in that only two transgenes have to
be combined. However, our system allows for complete on/off
control of expression. In addition, the existing inducible sys-
tems cannot be combined with and take advantage of the large
number of existing Cre-transgenic mouse strains deﬁning
tissue/cell type-speciﬁcities. Our results show that when
expressed from the ROSA26 locus, the baseline activity of
rtTA in the absence of inducer is not sufﬁcient to cause sig-
niﬁcant activation of a responsive promoter. This is in agree-
ment with the ﬁndings of Wutz and Jaenisch (42), who used
constitutive rtTA expression from the ROSA26 promoter. We
expect though that the ROSA26 locus placed rtTA could be a
limitation by providing only a given level of expression for
rtTA, which might not be high enough to reach sufﬁcient level
of induction of different responder tet-O-genes in certain
anatomical areas or cell types. Therefore, an obvious future
improvement of the presented system would be the establish-
ment of Cre conditional rtTA transgenes in several genomic
positions permissive to different level of overall expression.
Our ROSA26 placed Cre-conditional system could be the ﬁrst
member of this envisioned useful series.
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